Farydak Receives Positive Recommendation from European Medicines Agency Committee

On June 26, the Committee for Medicinal Products for Human Use (CHMP), an advisory committee of the European Medicines Agency (EMA), released a positive opinion regarding European approval of Farydak® (panobinostat) for the treatment of myeloma in certain cases. While this doesn't mean Farydak has been approved, it's an important first step in the EMA's process. CHMP's statement in particular supports the use of Farydak in combination with Velcade® and dexamethasone for myeloma patients who have relapsed and have already tried at least two prior treatment regimens.
Source: International Myeloma Foundation - Category: Hematology Source Type: news